<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">Cerebral vasospasm</z:e> remains a major source of morbidity after aneurysmal <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) </plain></SENT>
<SENT sid="1" pm="."><plain>We demonstrate that <z:chebi fb="0" ids="9150">simvastatin</z:chebi> reduces serum markers of brain injury and attenuates vasospasm after SAH </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Patients with angiographically documented aneurysmal SAH were randomized within 48 hours of symptom <z:hpo ids='HP_0003674'>onset</z:hpo> to receive either <z:chebi fb="0" ids="9150">simvastatin</z:chebi> (80 mg daily; n=19) or placebo (n=20) for 14 days </plain></SENT>
<SENT sid="3" pm="."><plain>Plasma alanine aminotransferase, <z:chebi fb="0" ids="29995">aspartate</z:chebi> aminotransferase, and <z:chebi fb="2" ids="16919">creatine</z:chebi> phosphokinase were recorded weekly to evaluate laboratory evidence of <z:hpo ids='HP_0012115'>hepatitis</z:hpo> or <z:hpo ids='HP_0100614'>myositis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Serum markers of brain injury were recorded daily </plain></SENT>
<SENT sid="5" pm="."><plain>The primary end point of vasospasm was defined as clinical impression (delayed ischemic deficit not associated with rebleed, <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, or <z:hpo ids='HP_0000238'>hydrocephalus</z:hpo>) in the presence of &gt; or =1 confirmatory radiographic test (angiography or transcranial Doppler demonstrating mean V(<z:chebi fb="70" ids="34342">MCA</z:chebi>) &gt;160 m/sec) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: There were no significant differences in laboratory-defined transaminitis or <z:hpo ids='HP_0100614'>myositis</z:hpo> between groups </plain></SENT>
<SENT sid="7" pm="."><plain>No patients developed clinical symptoms of <z:hpo ids='HP_0003198'>myopathy</z:hpo> or <z:hpo ids='HP_0012115'>hepatitis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Plasma <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor and S100beta were decreased 3 to 10 days after SAH (P&lt;0.05) in patients receiving <z:chebi fb="0" ids="9150">simvastatin</z:chebi> versus placebo </plain></SENT>
<SENT sid="9" pm="."><plain>Highest mean middle cerebral artery transcranial Doppler velocities were significantly lower in the <z:chebi fb="0" ids="9150">simvastatin</z:chebi>-treated group (103+/-41 versus 149+/-47; P&lt;0.01) </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, vasospasm was significantly reduced (P&lt;0.05) in the <z:chebi fb="0" ids="9150">simvastatin</z:chebi>-treated group (5 of 19) compared with those who received placebo (12 of 20) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: The use of <z:chebi fb="0" ids="9150">simvastatin</z:chebi> as prophylaxis against delayed <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> after aneurysmal SAH is a safe and well-tolerated intervention </plain></SENT>
<SENT sid="12" pm="."><plain>Its use attenuates serum markers associated with brain injury and decreases the incidence of radiographic vasospasm and delayed ischemic deficit </plain></SENT>
</text></document>